MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • MELA Sciences, Inc. (MELA) Device Shown To Improve Melanoma Detection 1 comment
    Feb 23, 2012 5:34 PM | about stocks: SSKN

    MelaFind, a non-invasive, multispectral computer vision system developed by MELA Sciences, has been shown to improve melanoma detection in a recent study. The study, involving 179 dermatologists, was published online on Feb. 20 in the Archives of Dermatology.

    Before obtaining the MelaFind output, the average sensitivity - or ability to detect disease - of the dermatologists in the study was 69 percent; after obtaining the MelaFind output, the dermatologists' average sensitivity increased to 94 percent. The percentage of dermatologists detecting all of the present melanomas during the study rose from 13 percent to 70 percent with the aid of MelaFind. Specificity, or the ability to correctly rule out disease when it isn't present, also increased on MelaFind negative lesions during the study, resulting in a 17 percent reduction of biopsies of the histologically benign lesions.

    MelaFind recently received approval from the FDA. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin's surface. MelaFind analyzes the three-dimensional morphologic disorganization under the surface of the legion, providing an easy-to-interpret and unambiguous output that dermatologists can incorporate into their biopsy decision-making processes.

    MELA Sciences is performing a controlled launch of MelaFind in the northeastern U.S. and in several key cities in Germany. MELA Sciences will work with the participating dermatology practices to train and assist them as they incorporate MelaFind. This approach will serve as the basis for a more widespread distribution of MelaFind in the future.

    MELA Sciences is a medical device company that focuses on the design, development, and commercialization of non-invasive dermatological tools to aid in the detection of melanoma. MelaFind is the company's flagship product. In addition to its FDA approval for use in the United States, MelaFind has also received the CE Mark and has been approved for use in the European Union.

    For further information about the company, visit www.melasciences.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: SSKN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • jrusso9722
    , contributor
    Comments (131) | Send Message
    If 179 Dermatologists were involved in the latest sentitivity tests, then that bodes well for the number that will order MelaFind, in my view. I think we are on the brink (4 weeks) of a sales release, showing a healthy sale of MelaFind Systems to Derms,in Germany, and the USA. I've asked myself this question: What dermatologist would not want to be able to offer MelaFind to patients, given that missing a melanoma, could wind up taking the patient's life. Of course, the Dr. has to make money on the system, that's a given. I'm long Mela, and I'm expecting good news soon.
    26 Feb 2012, 07:13 PM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.